Protein Expression News and Research

RSS

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics, an immuno-oncology company developing novel therapeutics for the treatment of cancer, today announced that the US Food and Drug Administration has granted Orphan Drug Designation for MTG-201, an advanced biologic therapy targeting Dickkopf-3 gene defects in various cancers, for the treatment of malignant mesothelioma.

23 Aug 2015

Synthorx employs synthetic DNA technology to produce proteins containing novel amino acids

Synthorx Inc. announced today that the company has employed its proprietary protein expression system to successfully produce proteins containing novel amino acids. Using a semi-synthetic DNA template (containing the synthetic base pair X and Y), Synthorx scientists were able to produce RNA containing X and Y, which was used with an otherwise fully natural biological system, to efficiently direct the incorporation of multiple novel amino acids at different sites in proteins.

19 Aug 2015

Novel treatment target found for RV failure in PAH

Researchers have identified a molecular pathway by which downregulation of microRNA-126 contributes to right ventricular failure in patients with pulmonary arterial hypertension.

10 Aug 2015

RNA-binding protein ROQUIN regulates response to DNA damage

Messenger (mRNA) molecules are a key component of protein biosynthesis. They are first transcribed as a "working copy" of the DNA and then translated into protein molecules.

3 Aug 2015

Mayo Clinic researchers study HDAC inhibitors to find effective treatments for anaplastic thyroid cancer

In their bid to find the best combination of therapies to treat anaplastic thyroid cancer (ATC), researchers on Mayo Clinic's Florida campus demonstrated that all histone deacetylase (HDAC) inhibitors are not created equal.

24 Jul 2015

MD Anderson named one of Genome Characterization Centers

The University of Texas MD Anderson Cancer Center has been named a site for one of two new Genome Characterization Centers (GCC) funded through the National Cancer Institute.

23 Jul 2015

Domainex’s new integrated bioassay service platform accelerates progression of drug discovery projects

Domainex Ltd, a private drug discovery service company, today announces that it is launching an integrated bioassay service platform, BioassayBuilder.

2 Jul 2015

Scientists develop new technique to analyze bacterial populations

Scientists from the Icahn School of Medicine at Mount Sinai have developed a new technique to more precisely analyze bacterial populations, to reveal epigenetic mechanisms that can drive virulence. The new methods hold the promise of a potent new tool to offset the growing challenge of antibiotic resistance by bacterial pathogens.

16 Jun 2015

VENTANA ALK (D5F3) CDx Assay receives FDA approval

Ventana Medical Systems, Inc., a member of the Roche Group, today announced approval of the VENTANA ALK (D5F3) CDx Assay by the US Food and Drug Administration as a companion diagnostic to aid in the identification of patients for Pfizer's FDA approved targeted therapy, XALKORI (crizotinib).

15 Jun 2015

Study on how maternal proteins help regulate initial cell divisions during early development

Researchers in the University of Georgia's Regenerative Bioscience Center are visually capturing the first process of chromosome alignment and separation at the beginning of mouse development. The findings could lead to answers to questions concerning the mechanisms leading to birth defects and chromosome instability in cancer cells.

10 Jun 2015

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from five studies that demonstrate the clinical utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in helping to identify targeted treatment options for patients with rare and/or aggressive tumors.

1 Jun 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from three studies that demonstrate the utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in facilitating comparisons between tumors that share histological features.

1 Jun 2015

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Caris Life Sciences® today announced the presentation of data from two studies in which researchers utilized Caris Molecular Intelligence®, the company's panomic, comprehensive tumor profiling service, to identify potential therapeutic targets in patients with colorectal and pancreatic cancer subtypes, based on expression of the programmed cell death protein 1 (PD-1) and its ligand, PD-L1.

1 Jun 2015

Multiplatform biomarker analysis reveals new therapeutic options for squamous cell anal carcinomas

While squamous cell anal carcinomas are rare, representing only about 2% of digestive-system cancer diagnoses, these cancers, which are associated with the human papillomavirus (HPV), sometimes prove very difficult to treat, recurring or developing metastases following standard treatment.

30 May 2015

NYU chemists find that microRNA can serve as 'decoder ring' for understanding biological functions

MicroRNA can serve as a "decoder ring" for understanding complex biological processes, a team of New York University chemists has found. Their study, which appears in Proceedings of the National Academy of Sciences, points to a new method for decrypting the biological functions of enzymes and identifying those that drive diseases.

27 May 2015

RepliCel's autologous cell treatment for Achilles tendinosis to be presented at ISCT 2015

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today an upcoming poster presentation at the International Society for Cellular Therapy on RepliCel's autologous cell treatment for chronic Achilles tendinosis currently in a Phase 1/2 clinical trial.

21 May 2015

Researchers identify 22 genetic variations associated with increased risk of prostate cancer

Prostate cancer affects one out of every 6 men during their lifetime and is the second most common cause of cancer-related death for men in the United States, resulting in an estimated 27,500 deaths in 2015. Identifying those men who have a higher risk of developing prostate cancer may reduce mortality.

6 Apr 2015

Scientists identify small RNA molecule that can suppress cancer-causing genes in GBM

Northwestern Medicine scientists have identified a small RNA molecule called miR-182 that can suppress cancer-causing genes in mice with glioblastoma mulitforme (GBM), a deadly and incurable type of brain tumor.

6 Apr 2015

MD Anderson, NanoString Technologies collaborate to accelerate development of 'multi-omic' assays

The University of Texas MD Anderson Cancer Center and NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced a multi-year collaboration to accelerate the development and adoption of a new type of assay based on NanoString's nCounter Analysis System.

From NanoString Technologies 1 Apr 2015

Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

Caris Life Sciences today announced the presentation of a study that found drugs targeting specific pathways may have potentially significant benefit in a select subset of patients with uterine cancer. The study results were highlighted today in an oral presentation in a Plenary Session at the Society of Gynecologic Oncology 2015 Annual Meeting on Women's Cancer in Chicago, Ill.

30 Mar 2015

Protein Expression News and Research

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

Synthorx employs synthetic DNA technology to produce proteins containing novel amino acids

Novel treatment target found for RV failure in PAH

RNA-binding protein ROQUIN regulates response to DNA damage

Mayo Clinic researchers study HDAC inhibitors to find effective treatments for anaplastic thyroid cancer

MD Anderson named one of Genome Characterization Centers

Domainex’s new integrated bioassay service platform accelerates progression of drug discovery projects

Scientists develop new technique to analyze bacterial populations

VENTANA ALK (D5F3) CDx Assay receives FDA approval

Study on how maternal proteins help regulate initial cell divisions during early development

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Study findings underscore importance of PD-1/PD-L1 expression in oncogenic signaling pathways

Multiplatform biomarker analysis reveals new therapeutic options for squamous cell anal carcinomas

NYU chemists find that microRNA can serve as 'decoder ring' for understanding biological functions

RepliCel's autologous cell treatment for Achilles tendinosis to be presented at ISCT 2015

Researchers identify 22 genetic variations associated with increased risk of prostate cancer

Scientists identify small RNA molecule that can suppress cancer-causing genes in GBM

MD Anderson, NanoString Technologies collaborate to accelerate development of 'multi-omic' assays

Caris Life Sciences study may have potentially significant benefit in patients with uterine cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News